Effectiveness and safety of dupilumab for the treatment of prurigo nodularis in a French multicenter adult cohort of 16 patients

J Eur Acad Dermatol Venereol. 2020 Feb;34(2):e74-e76. doi: 10.1111/jdv.15957. Epub 2019 Oct 17.

Authors

A Calugareanu¹, M Jachiet^{1

2}, M Tauber³, A Nosbaum⁴, F Aubin⁵, L Misery⁶, C Droitcourt⁷, S Barbarot⁸, S Debarbieux⁴, A Saussine¹, M Bagot^{1

2}, A de Masson^{1

2}, J Sénéschal⁹, D Staumont-Sallé¹⁰, J-D Bouaziz^{1

2}; French Group of Research and Study in Atopic Dermatitis (Groupe de Recherche sur l'Eczéma Atopique, GREAT) from the French Society of Dermatology (SFD)

Affiliations

¹ Dermatology Department, Saint-Louis Hospital, APHP, Paris, France.
² Université de Paris, Paris, France.
³ Dermatology Department, Larrey Hospital, CHU Toulouse, Toulouse, France.
⁴ Dermatology Department, CHU Lyon Sud, Lyon, France.
⁵ Dermatology Department, Jean Minjoz Hospital, CHU Besançon, Besançon, France.
⁶ Dermatology Department, CHU Brest, Brest, France.
⁷ Dermatology Department, CHU Rennes, Rennes, France.
⁸ Dermatology Department, CHU Nantes, Nantes, France.
⁹ Dermatology Department, Saint-André Hospital, CHU Bordeaux, Bordeaux, France.
¹⁰ Dermatology Department, CHU Lille, Lille, France.

PMID: 31529718
DOI: 10.1111/jdv.15957

No abstract available

Publication types

Letter
Multicenter Study

MeSH terms

Adult
Antibodies, Monoclonal, Humanized / adverse effects
Antibodies, Monoclonal, Humanized / pharmacology
Antibodies, Monoclonal, Humanized / therapeutic use*
Cohort Studies
Female
France
Humans
Interleukin-4 Receptor alpha Subunit / drug effects
Male
Middle Aged
Prurigo / drug therapy*
Retrospective Studies

Substances

Antibodies, Monoclonal, Humanized
Interleukin-4 Receptor alpha Subunit
dupilumab